ARCH Venture Partners has outlined plans for a new $3 billion fund, described as its 14th, aiming to raise one of the largest venture capital batches in biotech investing. The move signals continued investor demand for early-stage platforms and therapeutics bets as the industry cycles through post-volatile capital allocation. For founders, a fund of this scale can translate to more follow-on capital and larger check sizes, particularly in modality areas where clinical timelines and validation steps require extended financing. The fund strategy will also be read for how ARCH allocates across preclinical versus late pre-Phase 1 opportunities. The headline matters for market liquidity because ARCH’s sizing often influences how other large managers calibrate their own fund targets and underwriting expectations.